25 Buruli ulcer is a neglected tropical disease caused by infection with Mycobacterium 26 ulcerans. In this study we used a previously reported strain of M. ulcerans, genetically 27 engineered to constitutively produce bioluminescence, to follow the progression of Buruli 28 ulcer in mice using an in-vivo imaging (IVIS®) system. We aimed to characterize a mouse 29 tail infection model for pathogenesis, as well as for pre-clinical vaccine and drug 30 development research for Buruli ulcer. Immune parameters, such as antibody titers and 31 cytokine levels, were determined throughout the course of the infection and histology 32 specimens were examined for comparison with human pathology. Nine out of ten (90%) 33 BALB/c mice infected subcutaneously with 10 5 M. ulcerans JKD8049 (containing 34 pMV306 hsp16+luxG13) exhibited light emission from the site of infection over the course 35 of the experiment indicating M. ulcerans growth in-vivo. Five out of ten (50%) animals 36 developed clinical signs of disease. Antibody titers were overall low and their onset was 37 late, as measured by responses to both heterogenous (bacterial whole cell lysate) and single 38 antigen (Hsp18) targets. IFN-γ, and IL-10 are reported to play a vital role in host control 39 of Buruli ulcer and these cytokines were elevated in animals with pathology. For mice with 40 advanced pathology, histology revealed clusters of acid-fast bacilli within subcutaneous 41 tissue 300-400 μm beneath the epidermis of the tail, with macrophage infiltration and 42 granuloma-formation resembling human Buruli ulcer. This study has shown the utility of 43 using bioluminescent M. ulcerans and IVIS® in a mouse tail infection model to study 44 Buruli ulcer infection.
88 current trial analysis is ongoing (ClinicalTrials.gov Identifier: NCT01659437) [10, 11] .
89 Progressed, larger lesions are often managed with surgical excision of the infected tissue 90 followed by functional repair and skin grafting [12] ; a recent study showed that the time-91 point for decision making on whether to intervene surgically or not does not matter for 92 overall healing outcomes [13] . No vaccine is available despite several efforts to employ 93 the BCG-vaccine or to develop novel vaccines [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . ulcerans [24, 27] . The footpad-model has been derived from experience with experimental 101 infection of M. leprae in mice [24, 28] . It has been used in numerous pre-clinical studies,
102
to mainly evaluate drug efficacy, but also vaccines for M. ulcerans [25, 26, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] . Tail   103 infection has been used to study pathology and vector research [27] and vaccinology [14] .
104
Given that Buruli ulcer in humans is a subcutaneous infection mostly occurring on the 105 lower and upper limbs [1, 42] , the mouse foot and tail are obvious sites to model the disease 106 and the absence of fur in mice allows for easy clinical observation at these sites. Tail 107 infection offers a cutaneous infection site that is not in contact with the environment as 108 much as the footpad so that contamination, re-distribution or loss of inoculum and animal 109 impairment in more advanced stages of the disease are less likely to occur. Also, it is a 110 more practical region for imaging than the footpad. Bioluminescent strains of M. ulcerans 111 have successfully been employed to evaluate drug efficacy in in-vitro and in-vivo drug 112 efficacy studies [36, 37, 41, 43] and in vector ecology studies of M. ulcerans [44] . Drug 113 efficacy studies used a luminometer to assess light emission from infected mouse footpads 114 [36, 41, 45] .
116
In this study, we aimed to employed the use of a bioluminescent reporter strain of M.
117 ulcerans to infect BALB/c mice and read out light emission using an in-vivo imaging positive correlation (r 2 = 0.98) between photons/s and CFU/ml ( Fig 1A) .
237
Establishment of mouse tail infection.
238
In order to evaluate virulence and to study murine infection, bioluminescent M. ulcerans 239 was injected subcutaneously into mouse tails. Ten BALB/c mice were inoculated with 240 3.3x10 5 CFU/ml M. ulcerans JKD8049 pMV306 hsp16+luxG13. This resulted in 90% (9 241 out of 10) of mice presenting measurable light emission on IVIS®-images. Other than at 242 the injection site at the tail, no other foci of infection as indicated by bioluminescence were 243 observed ( Fig 1B) . Fifty percent (5 out of 10) gradually developed macroscopically 244 apparent lesions resembling Buruli ulcer within 17 weeks ( Fig 1C) . None of the animals 245 showed other signs of illness than skin lesion that were restricted to the approximate sites 246 of injection.
248
Course of the infection as measured by bioluminescence 249
To study the course of the infection in terms of bacterial burden measured in 250 bioluminescence, mice were imaged weekly with the IVIS® system. Bioluminescence, 251 measured in emitted photons/s rose exponentially to a maximum of 1x10 7 in week seven 252 ( Fig 1D) , according to our standard curve, this equals about 5x10 6 CFU/ml ( Fig 1A) and
253 was associated with advanced, severe pathology ( onset of the antibody response was noted (Fig 2A) . Antibody titers reached higher levels 277 between week 11 and 17, but overall titers, were low (Fig 2A) . The response to M. ulcerans
278
Hsp18 and WCL was compared and no statistically significant difference (p > 0.05) was 279 found ( Fig 2B) . Furthermore, ELISA results in response to WCL at week 8 were compared 280 between animals with severe, moderate and no clinical pathology and no statistically 281 significant difference (p > 0.05) was found (Fig 2C,D) . at week 17 were compared. In the three mice that were culled prematurely due to rapidly 290 extending disease in week 8, elevated levels of IFN-γ and IL-10 were measured. Overall, 291 cytokine levels were very low for all assayed cytokines in week 17 regardless of clinical 292 state of the animal (Fig 3) .
294

Histopathology of lesions 295
In order to validate the model and study the pathology of M. ulcerans, histopathology was 296 performed on skin lesions and compared to those of humans described in the literature.
297
Specimens from infected tissue were subjected to histopathological analysis in Ziehl-
298
Neelsen and H&E-staining. Aggregates of acid-fast bacilli, M. ulcerans, were observed at 299 300 -400 μm beneath the epidermis ( Fig 4A) . Furthermore, epidermal hyperplasia and 300 immune cell infiltrates were apparent (Fig. 4) Fig 4) . 
331
We noticed a decline and plateauing of bioluminescence from week 8 onwards. This 332 phenomenon could be explained by a plateauing of the bacterial growth curve in the lesion 333 and transition into a stationary phase where less of the immunosuppressive toxin 334 mycolactone is produced and partial host control sets in which is reflected to some extent 335 by the rise of antibody titers around that time-point (Fig 2) . Fig 4) . A hypoxic state within the lesion might also decrease 340 bioluminescence and more research is needed to elucidate the usefulness of indicates that large parts of the population in endemic areas are exposed to 
